Scope and US Claims Analysis for Patent 10,294,242 (Crystalline Polymorph with Defined PXRD Peaks) and the US Patent Landscape
US Patent 10,294,242 is narrowly directed to a specific crystalline polymorph of a defined small-molecule scaffold (the (7S,13R)-11-fluoro-7,13-dimethyl tetrahydro-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one enantiomer) where identity is defined by powder X-ray diffraction (PXRD). Practically, enforcement risk is highest against manufacturers that market or use the same polymorphic solid form with the claimed 2θ peak set centered on 27.4±0.1°, and optionally additional peak combinations.
What claims does US Patent 10,294,242 cover for the crystalline polymorph?
Claim 1: Core novelty hook is a polymorph defined by PXRD identity (2θ=27.4±0.1°)
- Claim type: product-by-structure where structure is operationalized by PXRD peak presence.
- Active identity: crystalline polymorph of the specified (7S,13R) compound.
- Minimum PXRD requirement: a powder X-ray diffraction pattern comprising a peak at 2θ = 27.4 ± 0.1°.
This is the broadest claim in the set. It does not require the additional peaks of dependent claims to be present. For infringement, the key technical issue is whether the accused polymorph’s diffractogram includes the 27.4° region within the tolerance window and whether experimental conditions (instrument, calibration, radiation source, sample prep) are consistent with the patent’s test method.
Claims 2–20: Dependent claims tighten the PXRD “signature” to specific peak sets
All dependent claims require:
- the Claim 1 requirement (presence of 27.4±0.1°), plus
- additional peaks at one or more specified 2θ values (each ±0.1°).
The dependent-claim peak values appearing across the claim set are:
- 9.4, 16.1, 16.5, 18.8, 21.2, 22.8, 27.4 (all ±0.1°)
Two-peak dependent claim variants (Claims 3–8) lock in additional single peaks paired with 27.4:
- 27.4 & 22.8 (Claim 3)
- 27.4 & 21.2 (Claim 4)
- 27.4 & 18.8 (Claim 5)
- 27.4 & 16.5 (Claim 6)
- 27.4 & 16.1 (Claim 7)
- 27.4 & 9.4 (Claim 8)
Three-peak dependent claim variants (Claims 9–20 and their internal coverage) lock in 27.4 plus two additional peaks:
- 27.4 + 22.8 + 21.2 (Claim 9)
- 27.4 + 22.8 + 18.8 (Claim 10)
- 27.4 + 22.8 + 16.5 (Claim 11)
- 27.4 + 22.8 + 16.1 (Claim 12)
- 27.4 + 22.8 + 9.4 (Claim 13)
- 27.4 + 21.2 + 18.8 (Claim 14)
- 27.4 + 21.2 + 16.5 (Claim 15)
- 27.4 + 21.2 + 16.1 (Claim 16)
- 27.4 + 21.2 + 9.4 (Claim 17)
- 27.4 + 18.8 + 16.5 (Claim 18)
- 27.4 + 18.8 + 16.1 (Claim 19)
- 27.4 + 18.8 + 9.4 (Claim 20)
Claim 2 functions as a “fuller” signature that includes the full cluster of listed peaks:
- 9.4, 16.1, 16.5, 18.8, 21.2, 22.8, 27.4 all within ±0.1°.
What does the claim architecture imply for enforcement?
- The enforceable “identity” is polymorph-specific, not a formulation-specific feature.
- The claims are not limited to dosage form (no tablet/capsule/suspension language in the provided claim text), so enforcement focuses on the solid form sold/manufactured/imported.
- The primary design-around lever is typically:
- selecting a different polymorph that does not produce a peak at 27.4±0.1° under comparable PXRD conditions, or
- producing the same polymorph but ensuring the measured peak(s) fall outside tolerance windows by controlling measurement conditions (though this is risky for design-around, and courts often treat this as a factual PXRD-evidence dispute).
How broad is the polymorph scope: what “crystalline polymorph form” means operationally for PXRD infringement?
The claimed compound identity is fixed; polymorph identity is PXRD-defined
The compound scaffold is fixed by:
- (7S,13R) stereochemistry
- 11-fluoro, 7,13-dimethyl substitution pattern
- the specific fused/bridged heterocycle system named in the claim
So, the claim does not read on racemates or other stereochemical mixtures unless they still meet the exact “crystalline polymorph form of” phrasing and the solid contains that stereochemical substance.
The polymorph claim is product-by-analytic method
Because claims are defined by PXRD peak positions:
- infringement is typically evaluated by comparing the accused solid’s PXRD pattern against the claimed peak list within ±0.1° tolerances.
- the 27.4° peak is the “gate” for Claim 1.
- dependent claims then require combinations of additional peaks, which makes them narrower and more “signature-like.”
Commercial implication: PXRD signature targeting is the litigation battleground
For a Paragraph IV or patent infringement dispute involving this patent, the central evidence tends to be:
- PXRD of the commercial/API solid form (and sometimes batch-to-batch)
- expert testimony linking measurement practice to the patent’s tolerances
What patent landscape surrounds US 10,294,242 (other US patents, continuation coverage, or related polymorph patents)?
No dataset of co-pending/related US applications, family members, assignees, publication numbers, or prosecution history is provided in the prompt. Without those bibliographic inputs (title, assignee, earliest priority, publication number, related family members, and prosecution events), a complete landscape mapping of “what else is out there” cannot be produced accurately.
Accordingly, the only valid landscape analysis here is the scope of claim 1 through claim 20 and the practical design-around space implied by the PXRD-based definition.
When does US 10,294,242 lose exclusivity, and how does that affect generic entry risk?
No expiration/filing/priority data is provided in the prompt. Without the patent’s:
- filing date,
- earliest priority date,
- PTA status,
- any terminal disclaimer,
- and whether it is subject to adjustments,
a reliable exclusivity/expiration timeline cannot be stated.
Which generic or biosimilar pathways are relevant to a crystalline polymorph patent like 10,294,242?
This patent is a small-molecule crystalline polymorph claim (not biologic), so:
- the main regulatory route is ANDA-based generic entry for the corresponding drug product containing the same active ingredient and solid form.
- the key practical question for an ANDA is whether the applicant’s API and/or solid-state form is:
- the same polymorph (meeting Claim 1 at minimum), or
- a different polymorph that avoids the 27.4±0.1° peak.
A polymorph patent is often targeted in ANDA litigation via:
- carve-outs (if feasible)
- different polymorph selection
- or noninfringement arguments based on PXRD differences.
How strong is US 10,294,242 as a polymorph patent: scope vs. design-around options
Strengths (based on claim wording)
- Fixed analyte + fixed polymorph definition: the claim is anchored to a defined stereochemical scaffold and a PXRD peak gate (27.4±0.1°).
- Multiple dependent claims: the patent covers not only a minimal peak requirement but also several additional peak combinations, including a “full” multi-peak signature (Claim 2).
- Low ambiguity in peak selection: the peak list is explicit and relatively compact.
Weaknesses / pressure points (as a matter of claim construction risk)
- PXRD method sensitivity: because infringement depends on measured diffraction peaks with narrow tolerance (±0.1°), disputes may turn on technical measurement variability.
- If a competitor can consistently avoid the 27.4±0.1° peak, Claim 1 and all dependent claims fall away.
- If the competitor uses an equivalent solid that still contains the 27.4° peak, they may still be captured by Claim 1 even if the full dependent signatures are not met.
What formulations are protected by US 10,294,242?
Based on the provided claim text, this patent is not formulation-limited. It is directed to the crystalline polymorph form itself. That means:
- downstream formulation (tablet, capsule, etc.) is not expressly claimed in the snippet provided,
- but product enforcement can still occur if the accused formulation contains the infringing API solid form.
How does US 10,294,242 compare with typical polymorph patents (claim-by-XRD vs. process or hydrate claims)?
This patent sits in the subset of polymorph IP where:
- identity is defined by XRD peaks, not
- a process parameter or
- a chemical/thermal attribute.
Compared with broader Markush or “form can be characterized by XRD peaks” approaches, this claim set is:
- more operational (peak lists are explicit),
- narrower in coverage (requires meeting exact peak positions within tolerance).
Key Takeaways
- US Patent 10,294,242 claims a crystalline polymorph of a defined (7S,13R) fluorinated heterocycle with identity defined by PXRD.
- Claim 1 is the core: the polymorph must show a PXRD peak at 2θ = 27.4 ± 0.1°.
- Claims 2–20 add narrower dependent requirements by requiring 27.4 ± 0.1° plus additional peaks among 9.4, 16.1, 16.5, 18.8, 21.2, 22.8 (each ±0.1°), including one claim with a larger multi-peak signature.
- The infringement and design-around battlefield is whether an accused solid form produces the claimed 27.4° peak and the additional dependent peak combinations under comparable PXRD conditions.
- A full litigation-ready patent landscape (family, co-owned patents, Orange Book linkage, expiration) cannot be constructed from the prompt because bibliographic and regulatory listing inputs are not included.
FAQs
1) What PXRD peak is essential for infringement of US 10,294,242?
A peak at 2θ = 27.4 ± 0.1° is required by Claim 1, and therefore by every dependent claim.
2) Do dependent claims require all peaks in the two-peak or three-peak sets?
Yes. Each dependent claim specifies exact additional peaks (each ±0.1°) beyond 27.4.
3) How can a competitor avoid these claims in practice?
The most direct strategy implied by the claims is to use a polymorph whose PXRD pattern does not include the 27.4 ± 0.1° peak, or at least not under the measurement conditions that support the patent tolerances.
4) Does the patent require a particular dosage form (tablet, capsule)?
The provided claim text is not dosage-form limited; it is directed to the crystalline polymorph solid defined by PXRD.
5) Can a solid that matches Claim 1 still avoid dependent claims?
Yes. A solid can meet Claim 1 (27.4 ± 0.1°) yet fail to meet one or more dependent claims if it lacks the specific additional peaks required.
References
- US Patent 10,294,242 (claims as provided in prompt).
